应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
VRTX 福泰制药
交易中 09-22 11:31:59 EDT
524.38
+13.66
+2.67%
最高
525.97
最低
508.14
成交量
41.45万
今开
521.64
昨收
510.72
日振幅
3.49%
总市值
1,330亿
流通市值
1,330亿
总股本
2.54亿
成交额
2.15亿
换手率
0.16%
流通股本
2.54亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
福泰制药宣布Inaxaplin在特定AMKD患者群体中取得积极结果，第13周UACR显著降低42.7%
投资观察 · 21:06
福泰制药宣布Inaxaplin在特定AMKD患者群体中取得积极结果，第13周UACR显著降低42.7%
福泰制药：Inaxaplin在两种AMKD患者队列中均展现良好安全性与耐受性
美股速递 · 20:02
福泰制药：Inaxaplin在两种AMKD患者队列中均展现良好安全性与耐受性
福泰制药公布Inaxaplin针对APOL1介导肾病（AMKD）其他人群的2B期AMPLIFIED研究积极结果，并完成2/3期AMPLITUDE试验入组
美股速递 · 20:01
福泰制药公布Inaxaplin针对APOL1介导肾病（AMKD）其他人群的2B期AMPLIFIED研究积极结果，并完成2/3期AMPLITUDE试验入组
福泰制药：Inaxaplin显著降低UACR达42.7%——针对适度蛋白尿APKD患者展现积极疗效
美股速递 · 20:01
福泰制药：Inaxaplin显著降低UACR达42.7%——针对适度蛋白尿APKD患者展现积极疗效
福泰制药获Leerink Partners恢复覆盖，给予跑赢大盘评级及594美元目标价
美股速递 · 09-21 18:04
福泰制药获Leerink Partners恢复覆盖，给予跑赢大盘评级及594美元目标价
小摩上调Vertex目标价至560美元
中金财经 · 09-15
小摩上调Vertex目标价至560美元
异动解读｜福泰制药盘中下跌3.1%，报524.945美元
行情直击 · 09-08
异动解读｜福泰制药盘中下跌3.1%，报524.945美元
高盛9月“确信名单”更新：美股纳入福泰制药(VRTX.US) 欧股力推莱茵、Adyen和塔兰克斯
智通财经 · 09-02
高盛9月“确信名单”更新：美股纳入福泰制药(VRTX.US) 欧股力推莱茵、Adyen和塔兰克斯
高盛9月“确信名单”更新：美股纳入福泰制药 欧股力推莱茵、Adyen和塔兰克斯
智通财经 · 09-02
高盛9月“确信名单”更新：美股纳入福泰制药 欧股力推莱茵、Adyen和塔兰克斯
异动解读｜福泰制药盘中上涨3.04%，多重管线催化剂叠加分析师看好推动股价走强
行情直击 · 08-19
异动解读｜福泰制药盘中上涨3.04%，多重管线催化剂叠加分析师看好推动股价走强
异动解读｜福泰制药盘中上涨3.09%，多重管线催化剂叠加分析师看好推动股价走强
行情直击 · 08-19
异动解读｜福泰制药盘中上涨3.09%，多重管线催化剂叠加分析师看好推动股价走强
美股异动 | 因竞争对手的药物研发未达目标 福泰制药(VRTX.US)涨近7%
智通财经 · 08-10
美股异动 | 因竞争对手的药物研发未达目标 福泰制药(VRTX.US)涨近7%
美股异动 | 因竞争对手的药物研发未达目标 福泰制药(VRTX.US)涨近7%
智通财经 · 08-10
美股异动 | 因竞争对手的药物研发未达目标 福泰制药(VRTX.US)涨近7%
异动解读｜福泰制药盘中上涨9.21%，Q2业绩超预期叠加全年指引上调
行情直击 · 08-10
异动解读｜福泰制药盘中上涨9.21%，Q2业绩超预期叠加全年指引上调
异动解读｜福泰制药盘前上涨3.26%，Q2业绩超预期叠加多家机构上调目标价
行情直击 · 08-10
异动解读｜福泰制药盘前上涨3.26%，Q2业绩超预期叠加多家机构上调目标价
异动解读｜福泰制药盘中上涨3.05%，Q2营收超预期且上调全年指引
行情直击 · 08-04
异动解读｜福泰制药盘中上涨3.05%，Q2营收超预期且上调全年指引
Vertex 扩大领导团队，为下一阶段增长注入强劲动力
投资观察 · 08-04
Vertex 扩大领导团队，为下一阶段增长注入强劲动力
非阿片止痛药新锐Latigo(LTGO.US)IPO拟最高募资2.88亿美元，Nav1.8抑制剂剑指福泰制药(VRTX.US)百亿市场
智通财经 · 08-04
非阿片止痛药新锐Latigo(LTGO.US)IPO拟最高募资2.88亿美元，Nav1.8抑制剂剑指福泰制药(VRTX.US)百亿市场
福泰制药重申2026年全年指引：GAAP与非GAAP研发、AI研发及销售管理费用预期不变
美股速递 · 08-04
福泰制药重申2026年全年指引：GAAP与非GAAP研发、AI研发及销售管理费用预期不变
AbCellera Biologics获2800万美元预付款及里程碑付款与阶梯式版税
美股速递 · 07-29
AbCellera Biologics获2800万美元预付款及里程碑付款与阶梯式版税
暂无数据
公司概况
公司名称：
福泰制药
所属市场：
NASDAQ
上市日期：
--
主营业务：
Vertex Pharmaceuticals Incorporated于1989年在马萨诸塞州注册成立，是一家全球性的生物技术公司，致力于科学创新，旨在为患有严重疾病的个人，特别是在专业市场创造变革性药物。该公司已开发出针对囊性纤维化、镰状细胞病、输血依赖性β地中海贫血和急性疼痛等病症的获批疗法。该公司不断创新，推进跨越各种严重疾病的下一代临床和研究项目，包括IgA肾病和1型糖尿病等。
发行价格：
--
{"stockData":{"symbol":"VRTX","market":"US","secType":"STK","nameCN":"福泰制药","latestPrice":524.38,"timestamp":1790091119353,"preClose":510.72,"halted":0,"volume":414524,"delay":0,"changeRate":0.026746553884711716,"floatShares":253718831,"shares":253718831,"eps":17.182146,"marketStatus":"交易中","change":13.66,"latestTime":"09-22 11:31:59 EDT","open":521.64,"high":525.97,"low":508.1426,"amount":214909113.88056,"amplitude":0.034906,"askPrice":524.81,"askSize":10,"bidPrice":524.23,"bidSize":11,"shortable":3,"etf":0,"ttmEps":17.182146,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1790107200000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":510.72,"preHourTrading":{"tag":"盘前","latestPrice":521.97,"preClose":510.72,"latestTime":"09:29 EDT","volume":8932,"amount":4600493.59,"timestamp":1790083799999,"change":11.25,"changeRate":0.022028,"amplitude":0.037365},"postHourTrading":{"tag":"盘后","latestPrice":511.8,"preClose":510.72,"latestTime":"19:54 EDT","volume":60125,"amount":30707256.046,"timestamp":1790034884948,"change":1.08,"changeRate":0.002115,"amplitude":0.002115},"volumeRatio":1.161373,"impliedVol":0.3011,"impliedVolPercentile":0.3347},"requestUrl":"/m/hq/s/VRTX/tweets","defaultTab":"tweets","newsList":[{"id":"1198157419","title":"福泰制药宣布Inaxaplin在特定AMKD患者群体中取得积极结果，第13周UACR显著降低42.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=1198157419","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198157419?lang=zh_cn&edition=full","pubTime":"2026-09-22 21:06","pubTimestamp":1790082369,"startTime":"0","endTime":"0","summary":"路透社9月22日消息——福泰制药 今日发布重大公告，披露其在APOL1介导肾病额外患者群体中开展的2b期AMPLIFIED研究取得积极成果。详细数据显示，对于伴有中度蛋白尿的AMKD患者，Inaxaplin在治疗第13周时使尿白蛋白肌酐比较基线下降了42.7%。两项研究队列均显示，Inaxaplin总体安全性和耐受性良好，未出现意外安全信号。值得注意的是，这是福泰制药在这两个特定亚群中首次公布Inaxaplin的临床数据，进一步拓展了该药物在AMKD治疗领域的潜在应用范围。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","IDNA","LU2237438978.USD","BIB","LU0256863811.USD","IE00B4R5TH58.HKD","LU0432979614.USD","BK4588","IE0009355771.USD","LU0417517546.SGD","IE00BFTCPJ56.SGD","LU0823416689.USD","IE00B2B36J28.USD","LU2236285917.USD","LU2324357040.USD","LU2456880835.USD","LU0079474960.USD","LU1093756168.USD","LU1069344957.HKD","SG9999001176.SGD","LU2417539215.USD","BK4533","LU1035775433.USD","LU1674673691.USD","LU2362541513.USD","SG9999013999.USD","SGXZ57979304.SGD","LU0289739699.SGD","SG9999001176.USD","LU0058720904.USD","LU2362541273.HKD","LU1093756325.SGD","VRTX","LU1430594728.SGD","IE00B894F039.SGD","BK4139","IE00B19Z9P08.USD","BK4532","IBBQ","LU1778281490.HKD","BK4567","IE00BJT1NW94.SGD","LU2468319806.SGD","LU0889565916.HKD","BBH","LU1674673428.USD","PBE","LU0234570918.USD","IE00B19Z3581.USD","IE0002270589.USD","IE00BJJMRZ35.SGD","TBXU","IE00B19Z3B42.SGD","LU2462157665.USD","GNMX","BK4585","IBB","LU2089984988.USD","IE00B19Z9Z06.USD","LU0109394709.USD","LU1585245621.USD","LU2362540622.SGD","IE0002141913.USD","LU0061475181.USD","IE00BZ9MQY76.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196050236","title":"福泰制药：Inaxaplin在两种AMKD患者队列中均展现良好安全性与耐受性","url":"https://stock-news.laohu8.com/highlight/detail?id=1196050236","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1196050236?lang=zh_cn&edition=full","pubTime":"2026-09-22 20:02","pubTimestamp":1790078535,"startTime":"0","endTime":"0","summary":"福泰制药近日披露，其候选药物Inaxaplin在两项针对APOL1介导肾病的临床试验队列中，表现出令人满意的安全性和耐受性特征。业内观察人士指出，Inaxaplin若能在后续研究中持续印证其价值，有望为AMKD这一难治性疾病带来突破性治疗选择。福泰制药此番公告，不仅回应了市场对管线进展的关切，也再次凸显了其在精准医疗赛道上的深耕意图。随着更多数据的积累，Inaxaplin的临床定位将愈发清晰，其对患者生活质量的实际改善程度也将接受更严苛的检验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756168.USD","IE00B19Z3B42.SGD","LU1430594728.SGD","LU2324357040.USD","LU0109394709.USD","LU2236285917.USD","BK4588","BK4532","IE0002141913.USD","IE00BJJMRZ35.SGD","LU1069344957.HKD","IE00B4R5TH58.HKD","IBBQ","LU0417517546.SGD","IE00BZ9MQY76.HKD","SG9999001176.USD","IE00BJT1NW94.SGD","LU0234570918.USD","LU2362541273.HKD","IE00B19Z3581.USD","LU2417539215.USD","LU0058720904.USD","IE0009355771.USD","LU0432979614.USD","LU0823416689.USD","IE00B19Z9Z06.USD","LU2362541513.USD","IE00B19Z9P08.USD","LU0061475181.USD","BK4567","IBB","LU1778281490.HKD","LU2237438978.USD","GNMX","LU1674673428.USD","LU2089984988.USD","LU2362540622.SGD","BK4533","VRTX","LU1674673691.USD","LU0320765992.SGD","IE00BFTCPJ56.SGD","TBXU","BK4139","SGXZ57979304.SGD","LU1093756325.SGD","IE00B2B36J28.USD","IE0002270589.USD","BK4585","SG9999013999.USD","SG9999001176.SGD","BIB","LU2456880835.USD","LU1035775433.USD","LU2462157665.USD","IDNA","LU0079474960.USD","LU0889565916.HKD","BBH","IE00B894F039.SGD","LU1585245621.USD","LU2468319806.SGD","PBE","LU0256863811.USD","LU0289739699.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160767959","title":"福泰制药公布Inaxaplin针对APOL1介导肾病（AMKD）其他人群的2B期AMPLIFIED研究积极结果，并完成2/3期AMPLITUDE试验入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1160767959","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160767959?lang=zh_cn&edition=full","pubTime":"2026-09-22 20:01","pubTimestamp":1790078494,"startTime":"0","endTime":"0","summary":"福泰制药今日宣布，其候选药物Inaxaplin在针对APOL1介导肾病其他患者群体的2B期AMPLIFIED研究中，取得了令人鼓舞的积极数据。与此同时，公司还确认，备受瞩目的2/3期AMPLITUDE注册试验已顺利达成全部患者入组目标。目前，该疾病在全球范围内缺乏针对性治疗手段，Inaxaplin有望为患者带来突破性的治疗选择。业内分析人士认为，AMPLIFIED研究的积极结果以及AMPLITUDE试验的顺利入组，进一步巩固了福泰制药在肾脏病精准医疗领域的领先地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B2B36J28.USD","LU1585245621.USD","IE0009355771.USD","LU0256863811.USD","LU2362541273.HKD","IE0002270589.USD","LU0889565916.HKD","IE0002141913.USD","LU2462157665.USD","LU0058720904.USD","LU0432979614.USD","SG9999001176.SGD","LU0109394709.USD","IE00BJT1NW94.SGD","LU2324357040.USD","LU0079474960.USD","IE00B19Z9P08.USD","PBE","LU2468319806.SGD","BIB","VRTX","IE00B19Z9Z06.USD","BK4585","BK4139","IE00BZ9MQY76.HKD","LU2417539215.USD","SG9999001176.USD","TBXU","GNMX","LU2237438978.USD","IE00B4R5TH58.HKD","IE00B894F039.SGD","LU1093756168.USD","LU1430594728.SGD","LU1035775433.USD","IE00BFTCPJ56.SGD","BBH","LU2236285917.USD","IBB","LU0289739699.SGD","LU0320765992.SGD","IE00BJJMRZ35.SGD","LU0417517546.SGD","BK4533","LU1093756325.SGD","LU2362541513.USD","LU1674673428.USD","IDNA","BK4588","LU0823416689.USD","BK4532","SG9999013999.USD","LU1674673691.USD","LU0061475181.USD","BK4567","LU1069344957.HKD","LU2456880835.USD","LU0234570918.USD","LU2089984988.USD","SGXZ57979304.SGD","IE00B19Z3B42.SGD","LU2362540622.SGD","LU1778281490.HKD","IE00B19Z3581.USD","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191181268","title":"福泰制药：Inaxaplin显著降低UACR达42.7%——针对适度蛋白尿APKD患者展现积极疗效","url":"https://stock-news.laohu8.com/highlight/detail?id=1191181268","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191181268?lang=zh_cn&edition=full","pubTime":"2026-09-22 20:01","pubTimestamp":1790078474,"startTime":"0","endTime":"0","summary":"生物制药巨头福泰制药近日披露了一项令人瞩目的临床数据：其候选药物Inaxaplin在治疗伴有适度蛋白尿的常染色体显性多囊肾病患者中，于第13周时使尿白蛋白肌酐比较基线大幅下降42.7%。值得关注的是，这项数据凸显了Inaxaplin在降低蛋白尿方面的显著潜力，而蛋白尿正是衡量肾脏损伤程度及预测疾病进展风险的关键生物标志物。尽管现有数据展现出鼓舞人心的信号，但业界普遍认为，要全面评估Inaxaplin的长期获益与安全性，尚需更大规模、更长周期的临床验证。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B2B36J28.USD","LU1585245621.USD","IE0009355771.USD","LU0256863811.USD","LU2362541273.HKD","IE0002270589.USD","LU0889565916.HKD","IE0002141913.USD","LU2462157665.USD","LU0058720904.USD","LU0432979614.USD","SG9999001176.SGD","LU0109394709.USD","IE00BJT1NW94.SGD","LU2324357040.USD","LU0079474960.USD","IE00B19Z9P08.USD","PBE","LU2468319806.SGD","BIB","VRTX","IE00B19Z9Z06.USD","BK4585","BK4139","IE00BZ9MQY76.HKD","LU2417539215.USD","SG9999001176.USD","TBXU","GNMX","LU2237438978.USD","IE00B4R5TH58.HKD","IE00B894F039.SGD","LU1093756168.USD","LU1430594728.SGD","LU1035775433.USD","IE00BFTCPJ56.SGD","BBH","LU2236285917.USD","IBB","LU0289739699.SGD","LU0320765992.SGD","IE00BJJMRZ35.SGD","LU0417517546.SGD","BK4533","LU1093756325.SGD","LU2362541513.USD","LU1674673428.USD","IDNA","BK4588","LU0823416689.USD","BK4532","SG9999013999.USD","LU1674673691.USD","LU0061475181.USD","BK4567","LU1069344957.HKD","LU2456880835.USD","LU0234570918.USD","LU2089984988.USD","SGXZ57979304.SGD","IE00B19Z3B42.SGD","LU2362540622.SGD","LU1778281490.HKD","IE00B19Z3581.USD","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147475205","title":"福泰制药获Leerink Partners恢复覆盖，给予跑赢大盘评级及594美元目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1147475205","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1147475205?lang=zh_cn&edition=full","pubTime":"2026-09-21 18:04","pubTimestamp":1789985058,"startTime":"0","endTime":"0","summary":"Leerink Partners近日宣布恢复对福泰制药的覆盖研究，并给予该股\"跑赢大盘\"评级。这家华尔街投行同时将目标价设定为594美元，彰显其对福泰制药未来走势的乐观预期。这一动作引发市场广泛关注——毕竟，Leerink Partners在生物医药领域的分析素以严谨著称。其恢复覆盖并给出积极评级，无疑为投资者注入了一针强心剂。值得注意的是，这一评级决定恰逢生物科技板块整体回暖之际。多重因素交织下，福泰制药的股价表现或将迎来新的催化剂。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002141913.USD","IE00B19Z3581.USD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","LU2089984988.USD","PBE","SGXZ57979304.SGD","LU0079474960.USD","LU0432979614.USD","SG9999001176.USD","BBH","IE00B19Z9P08.USD","LU1778281490.HKD","GNMX","IDNA","LU0109394709.USD","LU1093756325.SGD","IE00BJJMRZ35.SGD","TBXU","IE00BZ9MQY76.HKD","LU2468319806.SGD","LU1093756168.USD","LU0289739699.SGD","LU0889565916.HKD","SG9999001176.SGD","VRTX","LU0234570918.USD","IE0009355771.USD","LU0417517546.SGD","BK4567","LU0320765992.SGD","LU0058720904.USD","BIB","LU1035775433.USD","BK4139","LU1585245621.USD","LU1674673691.USD","LU2362541273.HKD","LU0061475181.USD","LU2462157665.USD","BK4533","IBBQ","BK4532","IE00B19Z9Z06.USD","LU2236285917.USD","LU2362541513.USD","SG9999013999.USD","LU2362540622.SGD","LU0256863811.USD","IBB","BK4588","IE00BFTCPJ56.SGD","BK4585","LU1674673428.USD","IE00B19Z3B42.SGD","LU2324357040.USD","LU2237438978.USD","IE0002270589.USD","IE00BJT1NW94.SGD","LU1430594728.SGD","LU1069344957.HKD","LU2456880835.USD","LU0823416689.USD","IE00B894F039.SGD","LU2417539215.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667618474","title":"小摩上调Vertex目标价至560美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2667618474","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667618474?lang=zh_cn&edition=full","pubTime":"2026-09-15 10:57","pubTimestamp":1789441023,"startTime":"0","endTime":"0","summary":"摩根大通将Vertex Pharmaceuticals的目标价从515美元上调至560美元，维持“增持”评级。(格隆汇)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260915/32369857.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["VERX","UDN","UUP","VRTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179668253","title":"异动解读｜福泰制药盘中下跌3.1%，报524.945美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1179668253","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1179668253?lang=zh_cn&edition=full","pubTime":"2026-09-08 21:36","pubTimestamp":1788874615,"startTime":"0","endTime":"0","summary":"9月8日，福泰制药盘中下跌3.1%，报524.945美元/股，成交额3729.83万美元。福泰制药所在的生物科技行业中，个股表现分化，其中安进跌7.47%，艾伯维公司跌2.03%，Moderna跌1.82%，PDS Biotechnology Corporation涨172.36%，Roivant Sciences涨13.6%。大型生物科技股普遍承压，福泰制药跟随板块走弱。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664891714","title":"高盛9月“确信名单”更新：美股纳入福泰制药(VRTX.US) 欧股力推莱茵、Adyen和塔兰克斯","url":"https://stock-news.laohu8.com/highlight/detail?id=2664891714","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664891714?lang=zh_cn&edition=full","pubTime":"2026-09-02 15:20","pubTimestamp":1788333621,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4550","LU2324357040.USD","BK4533","BK4127","IE00BJJMRZ35.SGD","LU1674673691.USD","LU2237438978.USD","IDNA","BK4585","LU0942090050.USD","IBBQ","GNMX","LU1868836914.USD","LU1868836591.USD","LU0432979614.USD","BK4588","LU0289739699.SGD","LU2462157665.USD","LU0868494617.USD","LU1791807156.HKD","VGK","IEV","IE0009355771.USD","PBE","LU2471134523.USD","SG9999001176.USD","LU2468319806.SGD","LU0061475181.USD","LU2237443549.SGD","LU1868837300.USD","LU2456880835.USD","VRTX","IE00BZ9MQY76.HKD","LU0096364046.USD","LU2471134952.CNY","VXUS","IE0002141913.USD","LU1144417596.USD","LU2237443978.SGD","IE00B19Z9Z06.USD","LU1668664300.SGD","LU0868494708.USD","IBB","BBH","GSX","IE00B19Z9P08.USD","TBXU","SG9999001176.SGD","BIB","LU0251131958.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664891705","title":"高盛9月“确信名单”更新：美股纳入福泰制药 欧股力推莱茵、Adyen和塔兰克斯","url":"https://stock-news.laohu8.com/highlight/detail?id=2664891705","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664891705?lang=zh_cn&edition=full","pubTime":"2026-09-02 15:20","pubTimestamp":1788333621,"startTime":"0","endTime":"0","summary":"进入秋季，高盛对其美国及欧洲市场的“确信名单”进行了更新，为投资者指明当前最看好的股票方向。本次调整中，美国名单新增一只大型生物科技股，欧洲名单则迎来三家新面孔。美国名单：新增福泰制药，移除盈透证券在美国市场，高盛将 $福泰制药$纳入确信名单，同时移除了 $盈透证券$，调整后名单保留23只股票。高盛还表示，塔兰克斯的国际零售业务是被低估的增长引擎。","market":"us","thumbnail":"https://static.tigerbbs.com/1b3684302211042d481cacf9066fbcca","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/1b3684302211042d481cacf9066fbcca"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490866.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1069344957.HKD","UNHW","SG9999001176.USD","LU2237443549.SGD","BBH","IEV","MSFU","IE00B2B36J28.USD","LU2265009873.SGD","SG9999001176.SGD","XYZ","IBKR","BK4504","VRTX","MSFW","BIB","BK4585","WFC","MSFX","LU1868836757.USD","CRNX","LU0889565916.HKD","VGK","IBB","IE0004091025.USD","IBBQ","BK4532","EL","IE0034235188.USD","MSFL","UNHU","LU2471134879.HKD","LU2362541273.HKD","IE00BFTCPJ56.SGD","LU1585245621.USD","BK4567","XYZG","LU0106831901.USD","LU1868837300.USD","UNHG","IDNA","LU2471134796.USD","MSFO","LU1868837136.USD","LU2417539215.USD","LU0345770993.USD","XYZY","LU2471134952.CNY","GSX","IE00BFXG1179.USD","LU2750360641.GBP","MSFC","LU2468319806.SGD","MSFT","TBXU","PBE","BK4533","IE00BJT1NW94.SGD","DAL","LU0109394709.USD","LU0432979614.USD","MSFD","COP","GNMX","IE00B19Z3581.USD","LU2456880835.USD","UN","UNH","LU2236285917.USD","LU2471134523.USD","MSFY","VXUS","IE0002270589.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187673248","title":"异动解读｜福泰制药盘中上涨3.04%，多重管线催化剂叠加分析师看好推动股价走强","url":"https://stock-news.laohu8.com/highlight/detail?id=1187673248","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187673248?lang=zh_cn&edition=full","pubTime":"2026-08-19 22:36","pubTimestamp":1787150201,"startTime":"0","endTime":"0","summary":"8月19日，福泰制药盘中上涨3.04%，报543.95美元/股，成交额1.24亿美元。此外，竞争对手囊性纤维化药物研发未达预期，进一步巩固了公司在该领域的主导地位。基本面方面，公司二季度营收33.34亿美元超市场预期，全年收入指引上调至131亿至132亿美元。多家机构维持买入评级，高盛目标价652美元、Jefferies目标价610美元，均显著高于当前股价。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192978278","title":"异动解读｜福泰制药盘中上涨3.09%，多重管线催化剂叠加分析师看好推动股价走强","url":"https://stock-news.laohu8.com/highlight/detail?id=1192978278","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192978278?lang=zh_cn&edition=full","pubTime":"2026-08-19 00:03","pubTimestamp":1787069031,"startTime":"0","endTime":"0","summary":"8月18日，福泰制药盘中上涨3.09%，报531.475美元/股，成交额2.2亿美元。消息面上，RBC Capital近期发布研报指出，福泰制药拥有多个潜在管线催化剂，整体风险收益比偏正面。此外，此前竞争对手药物研发未达预期，进一步强化了公司在囊性纤维化领域的领先地位。公司二季度营收33.34亿美元超预期，全年收入指引上调至131亿至132亿美元，多家机构维持买入评级，目标价普遍高于当前股价。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658930620","title":"美股异动 | 因竞争对手的药物研发未达目标 福泰制药(VRTX.US)涨近7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658930620","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658930620?lang=zh_cn&edition=full","pubTime":"2026-08-10 23:39","pubTimestamp":1786376356,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE0002270589.USD","LU1674673691.USD","LU2089984988.USD","SG9999001176.SGD","LU2362540622.SGD","LU0417517546.SGD","GNMX","IBBJ","LU1585245621.USD","LU2362541513.USD","LU2456880835.USD","IBB","LU1069344957.HKD","IE00B19Z9Z06.USD","LU2462157665.USD","LU0234570918.USD","LU1093756168.USD","LU2236285917.USD","LU1430594728.SGD","IE00BJT1NW94.SGD","BIB","VRTX","IBBQ","LU0320765992.SGD","LU2324357040.USD","LU0889565916.HKD","LU1035775433.USD","BK4588","BBH","IDNA","BK4567","LU1778281490.HKD","LU2417539215.USD","IE0002141913.USD","IE0009355771.USD","PBE","LU0289739699.SGD","TBXU","IE00B19Z3581.USD","IE00BZ9MQY76.HKD","IE00B19Z9P08.USD","LU0058720904.USD","BK4585","SGXZ57979304.SGD","SG9999013999.USD","IE00BFTCPJ56.SGD","LU0256863811.USD","SG9999001176.USD","LU1674673428.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658793062","title":"美股异动 | 因竞争对手的药物研发未达目标 福泰制药(VRTX.US)涨近7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658793062","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658793062?lang=zh_cn&edition=full","pubTime":"2026-08-10 23:39","pubTimestamp":1786376356,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周一，$福泰制药(VRTX)$(VRTX.US)早盘涨近7%，创历史新高;而竞争对手$Sionna Therapeutics(SION)$(SION.US)暴跌超90%，创记录新低。消息面上，SION表示，由于SION-719实验性囊性纤维化药物在中期临床试验中未能达到主要目标，公司将终止该药物的研发。投资者此前一直担忧SION可能对VRTX的核心囊性纤维化业务构成威胁，但此次试验失败消除了这一担忧。VRTX公司销售的Trikafta和Alyftrek用于治疗囊性纤维化——这是一种罕见、慢性且会缩短寿命的遗传性疾病，会导致肺部进行性损伤。","market":"fut","thumbnail":"https://static.tigerbbs.com/f156a54f9e4928ab062a3cdbe13dd440","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/f156a54f9e4928ab062a3cdbe13dd440"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478244.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B19Z9Z06.USD","PBE","IE00BJJMRZ35.SGD","LU2417539215.USD","IBB","IE00B2B36J28.USD","LU1093756168.USD","SGXZ57979304.SGD","IBBQ","TBXU","BBH","BK4139","IE0002141913.USD","LU1585245621.USD","LU2468319806.SGD","IE00BZ9MQY76.HKD","IE00B19Z9P08.USD","LU0417517546.SGD","LU0079474960.USD","VRTX","IE00B19Z3B42.SGD","LU0058720904.USD","LU0109394709.USD","LU0256863811.USD","SG9999001176.SGD","LU1430594728.SGD","LU2456880835.USD","LU1778281490.HKD","IE00B894F039.SGD","IBBJ","BIB","LU0234570918.USD","LU0061475181.USD","LU0320765992.SGD","LU1674673691.USD","LU2462157665.USD","BK4567","SG9999013999.USD","IE00BFTCPJ56.SGD","LU2362541273.HKD","IDNA","BK4532","LU2236285917.USD","LU1674673428.USD","LU2362541513.USD","SG9999001176.USD","IE00B4R5TH58.HKD","IE00B19Z3581.USD","GNMX","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170275964","title":"异动解读｜福泰制药盘中上涨9.21%，Q2业绩超预期叠加全年指引上调","url":"https://stock-news.laohu8.com/highlight/detail?id=1170275964","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170275964?lang=zh_cn&edition=full","pubTime":"2026-08-10 21:30","pubTimestamp":1786368641,"startTime":"0","endTime":"0","summary":"8月10日，福泰制药盘中上涨9.21%，报540.08美元/股，成交额1.14亿美元。消息面上，公司近日发布Q2财报，营收33.3亿美元超市场预期的32.3亿美元，同比增长12.5%；调整后EPS为4.73美元，同比增长4.6%。同时公司上调全年营收指引至131亿至132亿美元，高于此前的129.5亿至131亿美元及市场预期的130.6亿美元。此外，百亿美元收购Crinetics交易预计本季度完成，将新增内分泌业务支柱，进一步拓宽公司管线布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180549438","title":"异动解读｜福泰制药盘前上涨3.26%，Q2业绩超预期叠加多家机构上调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1180549438","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180549438?lang=zh_cn&edition=full","pubTime":"2026-08-10 19:08","pubTimestamp":1786360135,"startTime":"0","endTime":"0","summary":"8月10日，福泰制药盘前上涨3.26%，报515.0美元/股，成交额36.79万美元。消息面上，公司近日发布Q2财报，营收33.3亿美元超市场预期的32.3亿美元，同比增长12.5%；调整后EPS为4.73美元，同比增长4.6%。财报发布后，多家机构上调目标价：Cantor Fitzgerald上调至595美元，Rothschild上调至580美元，高盛此前已将目标价调升至652美元。此外，百亿美元收购Crinetics交易预计本季度完成，将新增内分泌业务支柱。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"福泰制药盘前上涨3.26%，Q2业绩超预期叠加多家机构上调目标价","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104230011","title":"异动解读｜福泰制药盘中上涨3.05%，Q2营收超预期且上调全年指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1104230011","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104230011?lang=zh_cn&edition=full","pubTime":"2026-08-04 22:14","pubTimestamp":1785852884,"startTime":"0","endTime":"0","summary":"8月4日，福泰制药盘中上涨3.05%，报481.47美元/股，成交额1.49亿美元。消息面上，公司公布第二季度业绩：调整后每股收益4.73美元，同比增长4.65%，符合市场预期；营收33.34亿美元，同比增长12.5%，超出分析师预期的32.32亿美元约1亿美元。更为关键的是，公司将全年营收指引从此前的129.5亿至131亿美元上调至131亿至132亿美元，高于FactSet一致预期的130.6亿美元。业绩公布后，Cantor Fitzgerald将目标价从590美元上调至595美元，维持增持评级。此前高盛亦将目标价上调至652美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"福泰制药盘中上涨3.05%，Q2营收超预期且上调全年指引","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117517951","title":"Vertex 扩大领导团队，为下一阶段增长注入强劲动力","url":"https://stock-news.laohu8.com/highlight/detail?id=1117517951","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117517951?lang=zh_cn&edition=full","pubTime":"2026-08-04 20:02","pubTimestamp":1785844955,"startTime":"0","endTime":"0","summary":"宾夕法尼亚州普鲁士王，2026年8月4日——全球间接税与合规领域的“决策到防御”先锋，Vertex Inc.，今日宣布其领导团队迎来三位新成员，旨在为公司下一阶段的蓬勃发展提供坚实支撑。他们的加入，将通过对人才、区域运营及技术创新的领导力扩展，进一步强化 Vertex 的全球增长战略。在 Vertex，她将负责全球人才与企业文化战略，构建起推动业务规模化发展所需的人才储备和组织能力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0757428866.USD","LU0061475181.USD","SG9999001176.USD","BBH","LU0256863811.USD","LU1093756168.USD","IE00B19Z9P08.USD","LU0109394709.USD","LU2456880835.USD","LU1585245621.USD","IE0002141913.USD","LU0058720904.USD","BK4585","IBB","LU0079474960.USD","BK4139","LU0566484027.USD","SG9999001176.SGD","LU2324357040.USD","LU1430594728.SGD","IE0002270589.USD","LU1559883803.SGD","IBBQ","BIB","IE00B19Z3581.USD","IE00B4R5TH58.HKD","LU1035775433.USD","BK4532","LU1069344957.HKD","IE00BJJMRZ35.SGD","LU2237438978.USD","LU1815336091.USD","IE00BFTCPJ56.SGD","LU2236285917.USD","VERX","LU0889565916.HKD","BK4555","IE00BZ9MQY76.HKD","IE00B19Z3B42.SGD","LU0823416689.USD","IDNA","BK4588","BK4604","TISI","LU2089984988.USD","SGXZ57979304.SGD","LU1674673691.USD","BK4567","LU2468319806.SGD","TM","LU2362540622.SGD","LU1778281490.HKD","LU0432979614.USD","TBXU","BK4533","LU2362541513.USD","LU2417539215.USD","GNMX","BK4120","VRTX","LU0289739699.SGD","BK4084","IE00BJT1NW94.SGD","IE00B2B36J28.USD","LU1674673428.USD","03160","BK4234","LU2462157665.USD","SG9999013999.USD","PBE","LU1093756325.SGD","LU2362541273.HKD","IE00B19Z9Z06.USD","PW","IE0009355771.USD","BK4023","LU0234570918.USD","BK4099","LU0417517546.SGD","LU0320765992.SGD","IE00B894F039.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656539622","title":"非阿片止痛药新锐Latigo(LTGO.US)IPO拟最高募资2.88亿美元，Nav1.8抑制剂剑指福泰制药(VRTX.US)百亿市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2656539622","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656539622?lang=zh_cn&edition=full","pubTime":"2026-08-04 16:59","pubTimestamp":1785833974,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00B19Z3581.USD","LU1585245621.USD","LU1674673428.USD","LU2456880835.USD","BK4139","BK4585","LU0889565916.HKD","LU0234570918.USD","FRHC","BK4532","IE0002141913.USD","LU0823416689.USD","LU2362541273.HKD","IE00B4R5TH58.HKD","GNMX","TBXU","IE00B19Z9Z06.USD","BIB","LU1778281490.HKD","IBBQ","VRTX","BK4533","IE00BZ9MQY76.HKD","LU0058720904.USD","LU0417517546.SGD","IE00B19Z3B42.SGD","LU1093756168.USD","SGXZ57979304.SGD","REDS","IE00BJT1NW94.SGD","LU2468319806.SGD","IBB","IE00B19Z9P08.USD","IE00BFTCPJ56.SGD","LU2362541513.USD","IE00BJJMRZ35.SGD","LU0256863811.USD","LU1093756325.SGD","BK4588","LU1430594728.SGD","KCE","BBH","IPOS","LU2324357040.USD","SG9999013999.USD","LU0289739699.SGD","BK4127","LTGO","IDNA","PBE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126575276","title":"福泰制药重申2026年全年指引：GAAP与非GAAP研发、AI研发及销售管理费用预期不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1126575276","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1126575276?lang=zh_cn&edition=full","pubTime":"2026-08-04 04:07","pubTimestamp":1785787669,"startTime":"0","endTime":"0","summary":"福泰制药（Vertex Pharmaceuticals）再次确认其2026年全年财务指引。在涵盖GAAP及非GAAP口径下的研发支出、AI研发投入以及销售、一般及管理费用（SG&A）方面，该公司均维持此前预期不变，未作出任何调整。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PBE","BK4588","IE00BJT1NW94.SGD","BK4139","IBBQ","LU2362540622.SGD","IE00B2B36J28.USD","LU0079474960.USD","LU0320765992.SGD","LU1430594728.SGD","LU2236285917.USD","TBXU","LU1585245621.USD","LU0889565916.HKD","LU1674673691.USD","LU2468319806.SGD","LU0058720904.USD","LU0256863811.USD","LU1069344957.HKD","LU1778281490.HKD","LU2324357040.USD","SG9999001176.USD","IE00B894F039.SGD","LU1674673428.USD","LU2462157665.USD","IDNA","IE00B19Z3581.USD","IE0002141913.USD","LU1035775433.USD","LU2237438978.USD","LU0417517546.SGD","LU2362541273.HKD","LU1093756325.SGD","IE0009355771.USD","BK4532","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","LU0234570918.USD","LU0109394709.USD","LU2362541513.USD","IE00BZ9MQY76.HKD","LU0432979614.USD","LU0823416689.USD","LU2417539215.USD","LU0289739699.SGD","IE00B19Z9P08.USD","SG9999013999.USD","IE00B19Z9Z06.USD","BIB","LU1093756168.USD","GNMX","IBB","LU2456880835.USD","BK4567","IE00BJJMRZ35.SGD","SG9999001176.SGD","SGXZ57979304.SGD","VRTX","BK4585","BBH","IE0002270589.USD","IE00B19Z3B42.SGD","LU2089984988.USD","LU0061475181.USD","BK4533"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185330982","title":"AbCellera Biologics获2800万美元预付款及里程碑付款与阶梯式版税","url":"https://stock-news.laohu8.com/highlight/detail?id=1185330982","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1185330982?lang=zh_cn&edition=full","pubTime":"2026-07-29 19:06","pubTimestamp":1785323188,"startTime":"0","endTime":"0","summary":"AbCellera Biologics公司宣布，将收到一笔高达2800万美元的预付款。除此之外，还有里程碑付款以及阶梯式特许权使用费加持。这笔交易架构颇为复杂，既有前期现金注入，也有后续潜在收益。预付款即刻到账，为研发管线提供弹药。里程碑款项则与特定项目进展挂钩，分期兑现。至于阶梯式版税，会随着产品销售额的攀升而逐步增加。整体来看，这一支付安排既保障了短期资金流，又锁定了长期回报空间。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ9MQY76.HKD","LU1430594728.SGD","IE0009355771.USD","BBH","BK4139","LU0234570918.USD","LU2417539215.USD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","LU1778281490.HKD","SG9999013999.USD","BK4532","TBXU","IE00BFTCPJ56.SGD","LU1069344957.HKD","LU1093756168.USD","LU0256863811.USD","SGXZ57979304.SGD","BK4567","IE0002141913.USD","LU2456880835.USD","LU0417517546.SGD","LU2362541513.USD","LU0823416689.USD","LU2324357040.USD","SG9999001176.USD","GNMX","LU0079474960.USD","BIB","IE00B19Z9P08.USD","LU2362541273.HKD","IBB","IE00B19Z3B42.SGD","LU1035775433.USD","VRTX","LU1674673428.USD","LU2237438978.USD","IE00B4R5TH58.HKD","BK4585","LU0432979614.USD","LU0061475181.USD","ABCL","IDNA","LU0289739699.SGD","IBBQ","BK4588","LU0058720904.USD","IE00B19Z9Z06.USD","BK4535","BK4121","LU0109394709.USD","LU1674673691.USD","SG9999001176.SGD","LU0320765992.SGD","IE0002270589.USD","IE00B19Z3581.USD","BK4533","LU2236285917.USD","LU2362540622.SGD","IE00BJT1NW94.SGD","IE00B894F039.SGD","LU1093756325.SGD","PBE","LU1585245621.USD","LU2462157665.USD","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vrtx.com","stockEarnings":[{"period":"1week","weight":-0.0169},{"period":"1month","weight":-0.0681},{"period":"3month","weight":0.0903},{"period":"6month","weight":0.1225},{"period":"1year","weight":0.3331},{"period":"ytd","weight":0.1265}],"compareEarnings":[{"period":"1week","weight":0.0166},{"period":"1month","weight":0.0102},{"period":"3month","weight":0.0544},{"period":"6month","weight":0.1776},{"period":"1year","weight":0.1654},{"period":"ytd","weight":0.1343}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Vertex Pharmaceuticals Incorporated于1989年在马萨诸塞州注册成立，是一家全球性的生物技术公司，致力于科学创新，旨在为患有严重疾病的个人，特别是在专业市场创造变革性药物。该公司已开发出针对囊性纤维化、镰状细胞病、输血依赖性β地中海贫血和急性疼痛等病症的获批疗法。该公司不断创新，推进跨越各种严重疾病的下一代临床和研究项目，包括IgA肾病和1型糖尿病等。","yearOnYearQuotes":[{"month":1,"riseRate":0.657143,"avgChangeRate":0.034393},{"month":2,"riseRate":0.457143,"avgChangeRate":0.001601},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.021959},{"month":4,"riseRate":0.6,"avgChangeRate":0.01636},{"month":5,"riseRate":0.571429,"avgChangeRate":0.076942},{"month":6,"riseRate":0.571429,"avgChangeRate":0.030748},{"month":7,"riseRate":0.457143,"avgChangeRate":-0.005619},{"month":8,"riseRate":0.638889,"avgChangeRate":0.048963},{"month":9,"riseRate":0.472222,"avgChangeRate":0.027629},{"month":10,"riseRate":0.542857,"avgChangeRate":0.000856},{"month":11,"riseRate":0.485714,"avgChangeRate":-0.02026},{"month":12,"riseRate":0.657143,"avgChangeRate":0.071588}],"exchange":"NASDAQ","name":"福泰制药","nameEN":"Vertex Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"福泰制药(VRTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供福泰制药(VRTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"福泰制药,VRTX,福泰制药股票,福泰制药股票老虎,福泰制药股票老虎国际,福泰制药行情,福泰制药股票行情,福泰制药股价,福泰制药股市,福泰制药股票价格,福泰制药股票交易,福泰制药股票购买,福泰制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"福泰制药(VRTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供福泰制药(VRTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}